Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko
Expectations For US Biosimilars ‘May Have Been Excessive’
In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.
You may also be interested in...
Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.
Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.